Physician profile
Matthew Lee
NPI 1225618689
$963.97
in general payments reported to CMS, 2019-2025
15 companies · $767 in 2025
The $767 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $197 · 2025: $767.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $964.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $963.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $258.45 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $124.08 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Stryker Corporation | $105.26 | 2024 | Scopis Ent |
| Lilly USA, LLC | $95.82 | 2025 | Mounjaro, Zepbound, Jardiance |
| Otsuka America Pharmaceutical, INC. | $89.51 | 2025 | Rexulti |
| Xeris Pharmaceuticals, INC. | $39.50 | 2025 | Gvoke Hypopen |
| Exact Sciences Corporation | $35.91 | 2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $35.80 | 2025 | Shingrix |
| Astellas Pharma US INC | $33.98 | 2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.85 | 2025 | Jardiance |
| Lundbeck LLC | $30.83 | 2025 | Rexulti |
| Hologic Sales and Service, LLC | $25.96 | 2024 | Aptima |
| Abbott Laboratories | $25.07 | 2025 | Freestyle Libre 3 |
| Abbvie INC. | $18.97 | 2025 | |
| Amgen INC. | $13.98 | 2025 | Repatha, Otezla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.